Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Andrés Poveda*, Anne Floquet, SOLO2/ENGOT-Ov21 investigators, Jonathan A. Ledermann, Rebecca Asher, Richard T. Penson, Amit M. Oza, Jacob Korach, Tomasz Huzarski, Sandro Pignata, Michael Friedlander, Alessandra Baldoni, Tjoung Won Park-Simon, Kenji Tamura, Gabe S. Sonke, Alla Lisyanskaya, Jae Hoon Kim, Elias Abdo Filho, Tsveta Milenkova, Elizabeth S. LowePhil Rowe, Ignace Vergote, Eric Pujade-Lauraine

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

230 Citations (Scopus)


Background: Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously been shown to extend progression-free survival versus placebo when given to patients with relapsed high-grade serous or endometrioid ovarian cancer who were platinum sensitive and who had a BRCA1 or BRCA2 (BRCA1/2) mutation, as part of the SOLO2/ENGOT-Ov21 trial. The aim of this final analysis is to investigate the effect of olaparib on overall survival. Methods: This double-blind, randomised, placebo-controlled, phase 3 trial was done across 123 medical centres in 16 countries. Eligible patients were aged 18 years or older, had an Eastern Cooperative Oncology Group performance status at baseline of 0–1, had histologically confirmed, relapsed, high-grade serous or high-grade endometrioid ovarian cancer, including primary peritoneal or fallopian tube cancer, and had received two or more previous platinum regimens. Patients were randomly assigned (2:1) to receive olaparib tablets (300 mg in two 150 mg tablets twice daily) or matching placebo tablets using an interactive web or voice-response system. Stratification was by response to previous chemotherapy and length of platinum-free interval. Treatment assignment was masked to patients, treatment providers, and data assessors. The primary endpoint of progression-free survival has been reported previously. Overall survival was a key secondary endpoint and was analysed in all patients as randomly allocated. Safety was assessed in all patients who received at least one treatment dose. This trial is registered with ClinicalTrials.gov, NCT01874353, and is no longer recruiting patients. Findings: Between Sept 3, 2013 and Nov 21, 2014, 295 patients were enrolled. Patients were randomly assigned to receive either olaparib (n=196 [66%]) or placebo (n=99 [34%]). One patient, randomised in error, did not receive olaparib. Median follow-up was 65·7 months (IQR 63·6–69·3) with olaparib and 64·5 months (63·4–68·7) with placebo. Median overall survival was 51·7 months (95% CI 41·5–59·1) with olaparib and 38·8 months (31·4–48·6) with placebo (hazard ratio 0·74 [95% CI 0·54–1·00]; p=0·054), unadjusted for the 38% of patients in the placebo group who received subsequent PARP inhibitor therapy. The most common grade 3 or worse treatment-emergent adverse event was anaemia (which occurred in 41 [21%] of 195 patients in the olaparib group and two [2%] of 99 patients in the placebo group). Serious treatment-emergent adverse events were reported in 50 (26%) of 195 patients receiving olaparib and eight (8%) of 99 patients receiving placebo. Treatment-emergent adverse events with a fatal outcome occurred in eight (4%) of the 195 patients receiving olaparib, six of which were judged to be treatment-related (attributed to myelodysplastic syndrome [n=3] and acute myeloid leukaemia [n=3]). Interpretation: Olaparib provided a median overall survival benefit of 12·9 months compared with placebo in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation. Although statistical significance was not reached, these findings are arguably clinically meaningful and support the use of maintenance olaparib in these patients. Funding: AstraZeneca and Merck.

Original languageEnglish
Pages (from-to)620-631
Number of pages12
JournalThe Lancet Oncology
Issue number5
Publication statusPublished - May 2021

Bibliographical note

Funding Information:
This study was sponsored by AstraZeneca and is part of an alliance between AstraZeneca and Merck, Kenilworth, NJ, USA. We thank the patients for their participation in this study, and their families, plus all investigators and onsite personnel, and the contributing study groups. Writing assistance was provided by Celine Goh, MBBS, from Mudskipper Business, funded by AstraZeneca and Merck, Kenilworth, NJ, USA. We thank Bénédicte Votan and Laure Jerber (ARCAGY-GINECO) for their role in project management.

Role of the funding source
The trial was designed by ENGOT and its lead group,
GINECO (Groupe d’Investigateurs Nationaux pour
l’Etude des Cancers Ovariens), in collaboration with the
sponsor, AstraZeneca. This article was written by the
authors, with medical writing support funded by the
sponsor. AstraZeneca was responsible for overseeing the
collection, analysis, and interpretation of the data.
Olaparib is being codeveloped by AstraZeneca and
Merck, and Merck provided input regarding
interpretation of the data.

Publisher Copyright:
© 2021 Elsevier Ltd


Dive into the research topics of 'Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial'. Together they form a unique fingerprint.

Cite this